2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

human IgG4 monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

47

Inhibitory Antibodies

10

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99631
    Garadacimab
    1 Publications Verification

    CSL312

    		 Factor Xa Cardiovascular Disease
    Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
    Garadacimab
  • HY-P99632
    Garetosmab

    REGN 2477

    		 TGF-β Receptor Inflammation/Immunology
    Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
    Garetosmab
  • HY-P990758
    Reflocibart

    		VEGFR Inflammation/Immunology
    Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Reflocibart
  • HY-P990755
    Pamvatamig

    		EGFR Inflammation/Immunology
    Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Pamvatamig
  • HY-P990691
    Vilamakitug

    XB-2001

    		 PD-1/PD-L1 Inflammation/Immunology
    Vilamakitug is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Vilamakitug
  • HY-P990702
    Pradusinstobart

    LVGN-3616

    		 PD-1/PD-L1 Inflammation/Immunology
    Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Pradusinstobart
  • HY-P990750
    Negalstobart

    		LAG-3 Inflammation/Immunology
    Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Negalstobart
  • HY-P990761
    Roconkibart

    		Interleukin Related Inflammation/Immunology
    Roconkibart is an anti-IL17A human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Roconkibart
  • HY-P99457
    Balstilimab

    AGEN2034

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .
    Balstilimab
  • HY-P990752
    Nezastomig

    REGN-5678

    		 CD28 Inflammation/Immunology
    Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Nezastomig
  • HY-P99305
    Metelimumab
    1 Publications Verification

    CAT-192; Anti-TGFB1 Recombinant antibody

    		 TGF-β Receptor Inflammation/Immunology
    Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
    Metelimumab
  • HY-P99357
    Crotedumab

    REGN1193; Anti-GCGR Reference antibody (crotedumab)

    		 GCGR Metabolic Disease
    Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
    Crotedumab
  • HY-P99695
    Lerdelimumab

    CAT-152

    		 TGF-beta/Smad Neurological Disease
    Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
    Lerdelimumab
  • HY-P99053
    Tralokinumab

    		Interleukin Related Inflammation/Immunology
    Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .
    Tralokinumab
  • HY-P99648
    Gosuranemab

    BMS-986168; IPN007; BIIB092

    		 Tau Protein Neurological Disease
    Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
    Gosuranemab
  • HY-P99399
    Semorinemab

    RG 6100; RO7105705; MTAU-9937A

    		 Tau Protein Neurological Disease
    Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
    Semorinemab
  • HY-P99786
    Pozelimab

    REGN3918

    		 Complement System Metabolic Disease
    Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
    Pozelimab
  • HY-P99114
    Sugemalimab

    		PD-1/PD-L1 Cancer
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
    Sugemalimab
  • HY-P99376
    Narsoplimab
    1 Publications Verification

    OMS 721; Anti-MASP2 Reference antibody (narsoplimab)

    		 SARS-CoV Infection
    Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
    Narsoplimab
  • HY-P99220
    Tabalumab

    LY2127399

    		 TNF Receptor Inflammation/Immunology Cancer
    Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
    Tabalumab
  • HY-P99263
    Inclacumab
    1 Publications Verification

    Anti-human selectin P Recombinant antibody

    		 P-selectin Cardiovascular Disease
    Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
    Inclacumab
  • HY-P99913
    Eflapegrastim

    		c-Fms Inflammation/Immunology Cancer
    Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
    Eflapegrastim
  • HY-P99194
    Evinacumab

    REGN1500

    		 ANGPTL Others Cardiovascular Disease Metabolic Disease
    Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
    Evinacumab
  • HY-P99203
    Cemiplimab

    		PD-1/PD-L1 Cancer
    Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
    Cemiplimab
  • HY-P99737
    Mirikizumab

    LY­3074828

    		 Interleukin Related Inflammation/Immunology
    Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
    Mirikizumab
  • HY-P99109
    Zimberelimab

    GLS-010; AB-122; WBP-3055

    		 PD-1/PD-L1 Cancer
    Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
    Zimberelimab
  • HY-P99453
    Azintuxizumab

    		ADC Antibody Cancer
    Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
    Azintuxizumab
  • HY-P99668
    Iparomlimab

    		PD-1/PD-L1 Cancer
    Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
    Iparomlimab
  • HY-P99299
    Lexatumumab

    HGS-ETR 2; ETR2-ST01

    		 Apoptosis Cancer
    Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
    Lexatumumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: